Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sonodynamic Therapy for PAD
NCT03318484Phase 2Withdrawn
- Sponsor
- The First Affiliated Hospital of Harbin Medical University
- Start
- Nov 2017
- Primary completion
- Nov 2019
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of cosiporfin sodium in Peripheral Arterial Disease (PAD), atherosclerosis, sponsored by The First Affiliated Hospital of Harbin Medical University. Planned start Nov 2017; status: withdrawn.
02
Drugs
cosiporfin sodium
03
Conditions
Peripheral Arterial Disease (PAD)atherosclerosis
Beyond the preview
Go deeper on NCT03318484.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03318484.